Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 150 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Maribavir for cytomegalovirus infections after transplant	Maribavir (SHP620; TAK-620)	Cytomegalovirus (CMV)	Infectious Disease	2020	View \| Download
Maralixibat for Progressive Familial Intrahepatic Cholestasis Type 2	Maralixibat chloride (SHP625)	Progressive familial intrahepatic cholestasis (PFIC)	Genetic Disorders , Hepatology	2020	View \| Download
Luspatercept for the treatment of adults with non-transfusion dependent beta-thalassaemia	Luspatercept (ACE-536; Reblozyl)	Beta thalassemia	Genetic Disorders , Haematology	2020	View \| Download
Lurbinectedin in addition to doxorubicin for small-cell lung cancer after prior platinum-containing therapy	Doxorubicin (Livatag; BA-003; Caelyx; Sarcodoxome; SP-1049C; Resmycin; JNS002; doxorubicin hydrochloride) , Lurbinectedin (PM01183; Zepzelca)	Small-cell lung cancer (SCLC)	Lung and Respiratory Cancer	2020	View \| Download
Lorlatinib for advanced ALK-positive non-small cell lung cancer – first line	Lorlatinib (PF-06463922; Lorviqua)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Lonafarnib for Hutchinson-Gilford Progeria syndrome and progeroid laminopathies	Lonafarnib (Sarasar; EBP994; SCH 66336; Zokinvy)	Progeria	Genetic Disorders	2020	View \| Download
LN-145 for recurrent, metastatic or persistent cervical carcinoma	LN-145	Cervical cancer	Female Reproductive Cancer	2020	View \| Download
Lisocabtagene maraleucel for transplant-eligible and ineligible, relapsed or refractory, aggressive B-cell non-Hodgkin lymphoma - second-line	Lisocabtagene maraleucel (Liso-cel; JCAR017)	Diffuse large B-cell lymphoma (DLBCL) , Follicular lymphoma , Non-Hodgkin lymphoma (NHL) , Primary mediastinal large B-cell lymphoma (PMBCL)	Haematological Cancer and Lymphomas	2020	View \| Download
Lisocabtagene maraleucel for relapsed or refractory, aggressive B-cell non-Hodgkin Lymphoma – second line	Lisocabtagene maraleucel (Liso-cel; JCAR017)	Non-Hodgkin lymphoma (NHL)	Haematological Cancer and Lymphomas	2020	View \| Download
Liposomal cytarabine-daunorubicin for treating relapsed or refractory acute myeloid leukaemia in paediatric patients.	CPX-351 (Vyxeos Liposomal) (fixed dose combination: Cytarabine; daunorubicin)	Acute myeloid leukaemia (AML)	Haematological Cancer and Lymphomas	2020	View \| Download